Mitchell S von Itzstein
Overview
Explore the profile of Mitchell S von Itzstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
von Itzstein M, Gwin M, Gupta A, Gerber D
Cancer J
. 2024 Jan;
30(1):22-26.
PMID: 38265922
Telemedicine represents an established mode of patient care delivery that has and will continue to transform cancer clinical research. Through telemedicine, opportunities exist to improve patient care, enhance access to...
12.
Han Y, Yang Y, Tian Y, Fattah F, von Itzstein M, Hu Y, et al.
bioRxiv
. 2023 Dec;
PMID: 38105939
Profiling the binding of T cell receptors (TCRs) of T cells to antigenic peptides presented by MHC proteins is one of the most important unsolved problems in modern immunology. Experimental...
13.
Ostmeyer J, Park J, von Itzstein M, Hsiehchen D, Fattah F, Gwin M, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37580069
Background: Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide...
14.
Mundra V, Yang Y, von Itzstein M, Fattah F, Gonugunta A, Hannan R, et al.
Transl Oncol
. 2023 Jun;
34:101689.
PMID: 37285748
Introduction: Preclinical studies have demonstrated the ability of radiation therapy (RT) to augment immune response and tumor control by immune checkpoint inhibitors (ICI). However, numerous clinical trials combining RT and...
15.
Ulndreaj A, Brinc D, Altan M, Pons-Belda O, Fernandez-Uriarte A, Mu-Mosley H, et al.
Clin Chem Lab Med
. 2022 Oct;
61(1):154-161.
PMID: 36287134
Objectives: Immune checkpoint inhibitors (ICIs) cause a variety of toxicities, including immune-related adverse events (irAEs), but there are no biomarkers to predict their development. Guidelines recommend measuring circulating cardiac troponin...
16.
Gonugunta A, von Itzstein M, Hsiehchen D, Le T, Rashdan S, Yang H, et al.
Clin Lung Cancer
. 2022 Oct;
24(1):11-17.
PMID: 36253271
Introduction: Antibiotic exposure is associated with worse clinical outcomes in patients receiving immune checkpoint inhibitors (ICI). We analyzed antibiotic prescription patterns in lung cancer and melanoma, two malignancies in which...
17.
von Itzstein M, Gerber D, Minna J
Transl Lung Cancer Res
. 2022 Sep;
11(8):1522-1525.
PMID: 36090641
No abstract available.
18.
Edmondson S, von Itzstein M, Reys B, Mayer M, Gagan J, Gerber D
JTO Clin Res Rep
. 2022 Jul;
3(8):100368.
PMID: 35875466
Introduction: Heritable lung cancer may occur in the context of germline mutations (Li-Fraumeni syndrome). Limited cases of intrafamily tumor genomic characteristics have been reported. Main Concerns Important Clinical Findings Primary...
19.
Gonugunta A, von Itzstein M, Gerber D
J Med Case Rep
. 2022 Jul;
16(1):289.
PMID: 35871685
Background: Pseudoprogression, the initial apparent worsening of cancer prior to eventual improvement, is a documented feature of immune checkpoint inhibitor administration and presents a challenge to clinicians distinguishing true progression...
20.
von Itzstein M, Gonugunta A, Wang Y, Sheffield T, Lu R, Ali S, et al.
Cancer Immunol Immunother
. 2022 May;
71(9):2183-2184.
PMID: 35596002
No abstract available.